Lite Strategy (LITS) Retained Earnings (2011 - 2026)
Lite Strategy (LITS) posted Retained Earnings of -$462.3 million for Q1 2026, down 5.4% on a QoQ basis from -$438.6 million in Q4 2025, and down 15.14% year-over-year from -$544.8 million in Q1 2025.
Analysis
Lite Strategy (LITS) Retained Earnings (2011 - 2026) Analysis & Trends
Lite Strategy has reported Retained Earnings for 16 years, with the latest figure at -$462.3 million in Q1 2026.
- On a quarterly basis, Retained Earnings fell 15.14% year-over-year to -$462.3 million in Q1 2026; TTM through Mar 2026 was -$462.3 million, a 15.14% decrease from a year earlier, with the FY2025 full-year figure at -$404.2 million, down 4.11% from the prior year.
- Retained Earnings was -$462.3 million for Q1 2026 at Lite Strategy, down from -$438.6 million in the prior quarter.
- The five-year high for Retained Earnings was -$349.6 million in Q3 2023, with the low at -$462.3 million in Q1 2026.
- Average Retained Earnings over 5 years is -$393.1 million, with a median of -$396.0 million recorded in 2023.
- The sharpest annual moves came in 2022 and 2023: Retained Earnings dropped 17.03% in 2022, then grew 10.54% in 2023.
- Over 5 years, Retained Earnings stood at -$380.5 million in 2022, then advanced by 5.21% to -$360.7 million in 2023, then retreated by 10.59% to -$398.9 million in 2024, then retreated by 9.95% to -$438.6 million in 2025, then slipped by 5.4% to -$462.3 million in 2026.
- The last three Retained Earnings figures came in at -$462.3 million (Q1 2026), -$438.6 million (Q4 2025), and -$407.8 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | -22.28 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 9.53 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 15.69 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 37.62 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 558.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 20.97 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 5.13 Bn |
| 10 | Lite Strategy | 38.03 Mn | 30.49 Mn | - | -462.30 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -462.30 Mn |
| Dec 31, 2025 | -438.60 Mn |
| Sep 30, 2025 | -407.80 Mn |
| Jun 30, 2025 | -404.16 Mn |
| Mar 31, 2025 | -401.50 Mn |
| Dec 31, 2024 | -398.90 Mn |
| Sep 30, 2024 | -396.23 Mn |
| Jun 30, 2024 | -388.22 Mn |
| Mar 31, 2024 | -369.81 Mn |
| Dec 31, 2023 | -360.70 Mn |
| Sep 30, 2023 | -349.62 Mn |
| Jun 30, 2023 | -406.00 Mn |
| Mar 31, 2023 | -396.00 Mn |
| Dec 31, 2022 | -380.53 Mn |
| Sep 30, 2022 | -390.80 Mn |
| Jun 30, 2022 | -374.16 Mn |
| Mar 31, 2022 | -358.10 Mn |
| Dec 31, 2021 | -349.40 Mn |
| Sep 30, 2021 | -337.22 Mn |
| Jun 30, 2021 | -319.71 Mn |